Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxyurea for Primary Stroke Prevention in Children With Sickle Cell Anemia in Nigeria
NCT06526117Phase 4Recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- Aug 2024
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hydroxyurea in sickle cell anemia (SCA), sponsored by Vanderbilt University Medical Center. Primary endpoint: Incidence Rate of Clinical Stroke or TIA at 5 years. Started Aug 2024; status: recruiting.
02
Drugs
hydroxyurea
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on NCT06526117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06526117.